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Abstract
Background: Lung cancer remains the leading cause of cancer-related deaths worldwide. The recurrence rate ranges from
35–50% among early stage non-small cell lung cancer patients. To date, there is no fully-validated and clinically applied
prognostic gene signature for personalized treatment.
Methodology/Principal Findings: From genome-wide mRNA expression profiles generated on 256 lung adenocarcinoma
patients, a 12-gene signature was identified using combinatorial gene selection methods, and a risk score algorithm was
developed with Naı ¨ve Bayes. The 12-gene model generates significant patient stratification in the training cohort HLM & UM
(n=256; log-rank P=6.96e-7) and two independent validation sets, MSK (n=104; log-rank P=9.88e-4) and DFCI (n=82; log-
rank P=2.57e-4), using Kaplan-Meier analyses. This gene signature also stratifies stage I and IB lung adenocarcinoma
patients into two distinct survival groups (log-rank P,0.04). The 12-gene risk score is more significant (hazard ratio=4.19,
95% CI: [2.08, 8.46]) than other commonly used clinical factors except tumor stage (III vs. I) in multivariate Cox analyses. The
12-gene model is more accurate than previously published lung cancer gene signatures on the same datasets. Furthermore,
this signature accurately predicts chemoresistance/chemosensitivity to Cisplatin, Carboplatin, Paclitaxel, Etoposide,
Erlotinib, and Gefitinib in NCI-60 cancer cell lines (P,0.017). The identified 12 genes exhibit curated interactions with
major lung cancer signaling hallmarks in functional pathway analysis. The expression patterns of the signature genes have
been confirmed in RT-PCR analyses of independent tumor samples.
Conclusions/Significance: The results demonstrate the clinical utility of the identified gene signature in prognostic
categorization. With this 12-gene risk score algorithm, early stage patients at high risk for tumor recurrence could be
identified for adjuvant chemotherapy; whereas stage I and II patients at low risk could be spared the toxic side effects of
chemotherapeutic drugs.
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Introduction
Lung cancer is the leading cause of cancer-related deaths in
industrialized countries [1]. Local and distant recurrence is the major
cause oftreatment failure (i.e. deaths)in lung cancer.Currently,surgery
is the foremost treatment option for patients with stage I non-small cell
lung cancer (NSCLC). However, 35–50% of stage I NSCLC patients
will relapse within 5 years [2,3]. It remains a critical challenge to
determine the risk for recurrence in early-stage cancer patients. Patients
at high risk for recurrence might benefit from adjuvant chemotherapy,
whereas those with a low risk for tumor recurrence might be spared of
the side effects of chemotherapy. Following this, another critical issue in
clinics is to determine an individual patient’s predisposition to a specific
anticancer drug. The emerging use of biomarkers may enable
physicians to make treatment decisions based on the specific
characteristics of individual patients and their tumor, instead merely
of on population statistics [4].
The advances in microarray technologies yield promise in the
molecular prediction of individual clinical outcome. Such success
is manifested by the commercial gene tests for breast cancer,
Oncotype DX [5] and MammaPrint [6,7]. Nevertheless, the high
dimensionality of the data has complicated major diagnostic and
prognostic breakthroughs [8] and puts a premium on innovative
data mining methods. In current biomarker identification studies,
genes are ranked according to their association with the clinical
outcome, and the top ranked genes are included in the classifier. It
has been noted that individual biomarkers showing strong
association with the outcome are not necessarily good classifiers
[9–11]. Furthermore, each individual gene selection algorithm has
different strengths and limitations. A hybrid model combining
multiple gene selection methods could better identify novel
biomarkers from high-throughput data for clinical utility.
There have been a few studies on lung cancer prognosis by
transcriptional profiling [12–19]. To date, there is no fully-
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recurrence [20]. This study presents a combinatorial gene
selection system for the identification of a 12-gene lung cancer
prognostic signature. This 12-gene signature is more accurate
compared with previously published signatures in a multi-
institutional study of lung adenocarcinoma (n=442) [19]. This
12-gene signature could identify stage I and stage II patients who
might benefit from adjuvant chemotherapy and who could be
spared of it. Quantitative RT-PCR analyses of independent
NSCLC tissue samples confirmed the gene expression patterns of
the identified biomarkers in terms of tumor characteristics. A
functional pathway analysis then revealed that the signature genes
had interactions with well established cancer hallmarks, indicating
the important roles of the signature genes in tumor initiation and
progression. Furthermore, the 12-gene signature accurately
predicted chemoresistance and chemosensitivity to Cisplatin,
Carboplatin, Paclitaxel (Taxol), Etoposide, Gefitinib and Erlotinib
in a panel of 60 cancer cell lines (NCI-60).
Results
Prognostic model system
In the post-genomic era, hybrid models that take advantage of
different algorithms in different stages of gene selection are
needed for biomarker discovery and disease classification. In this
study, we combined statistical methods and machine learning
algorithms to identify prognostic biomarkers of lung adenocar-
cinoma. The surgical resections collected from the University of
Michigan Cancer Center (UM) and Moffitt Cancer Center
(HLM) form the training set (n=256), whereas the samples
obtained from Memorial Sloan-Kettering Cancer Center (MSK,
n=104) and the Dana-Farber Cancer Institute (DFCI, n=82)
constitute two independent validation sets. The clinical charac-
teristics of the patient cohorts were described in the previous
publication [19].
The prognostic study includes three phases (Fig. 1): 1)
identification of a small set of signature genes by combining
Significance Analysis of Microarrays (SAM) [21], different-
variance t-tests, and Relief algorithm from genome-scale transcrip-
tional profiles of the training cohort (UM & HLM), 2) construction
of a classifier using Naive Bayes algorithm to predict overall survival
in lung cancer patients, and 3) validation of the gene expression-
based prognostic model in two independent patient cohorts (MSK
and DFCI). Independent test sets were used in the model
validation and evaluation of the identified gene signature over
previously published lung cancer prognostic signatures.
Identification of a 12-gene prognostic signature
A combinatorial scheme with multiple gene selection methods
was adopted in the process of identifying a lung cancer prognostic
gene signature. The first step selected candidate genes from 22,283
probes quantified on the training cohort (n=256). A combination
of t-tests and SAM was then used to select genes with expression
levels significantly different between low-risk (patient who survived
longer than 5 years) and high-risk (those who died within 5 years
following surgery) groups with a predefined false discovery rate.
Twenty-seven censored cases with follow-up time less than 5 years
were removed from this analysis due to the uncertainty of patient
post-operative status. Specifically, a different-variance t-test
selected 718 genes with significant differential expression
(P,0.01) between the two prognosis groups. To control false
discovery rate (FDR), SAM was used to select 1,431 genes that
significantly differentiated the two prognostic groups at a FDR of
25% (delta=0.46). There were 583 genes selected by both t-tests
and SAM, and these were considered for the next stage of the
analysis.
In order to refine the gene set into a more feasible size for
clinical application, Relief algorithm implemented in WEKA 3.4
was used to rank each of these 583 genes in terms of the power to
separate low-risk and high-risk groups. This ranked list was used in
a step-wise forward selection to identify a gene subset with the
highest prognostication accuracy. Specifically, starting from the
top ranked gene, one gene was added at each step to the gene set,
until the classification accuracy could not be improved by adding
one more gene. This gene set was used to classify good-prognosis
and poor-prognosis groups with Naı ¨ve Bayes algorithm. This
process stopped when the addition of a new gene did not increase
the classification accuracy as evaluated in a 10-fold cross
validation. As a result, a 12-gene signature (Table 1) was identified
which could provide the best prediction for overall survival.
Survival prediction using 12-gene prognostic model
Using mRNA expression profiles of the identified 12 genes as
predictors, a prognostic classifier was constructed to stratify
patients into low-risk (5-year survival) and high-risk (non-5-year
survival) groups. The Naı ¨ve Bayes classifier implemented in WEKA
3.4 was used in the classification on UM & HLM training samples
(low-risk n=104; high-risk n=125). Twenty-seven censored cases
without sufficient follow-up information were removed in the
model construction. Priors estimated by the model are 0.45 for
low-risk class and 0.55 for high-risk class. Other parameters of the
trained Naı ¨ve Bayes model, including the mean and standard
deviation for each of the 12 genes in both low- and high-risk
groups, are listed in Table 2.
The Naı ¨ve Bayes classifier computes the posterior probability of
death within 5 years after surgery in each patient. This posterior
probability represents the risk for tumor recurrence in patients,
since recurrence is the major cause of treatment failure (i.e. death)
in lung cancer. Based on the posterior probability, a patient is
classified into the high-risk group if the value is greater than 0.5; or
into the low-risk group otherwise. The training model was
evaluated in a 10-fold cross validation. Without parameter re-
estimation, this model was then used to predict posterior
probability representing the risk for tumor recurrence in each
patient in two test sets (MSK and DFCI), as well as the censored
cases left out of the model construction. The distribution of the
posterior probability of 442 patients in this study was illustrated in
Fig. 2A. After obtaining the predicted outcomes, Kaplan-Meier
(KM) analysis was carried out to estimate the average survival
probability at the 5-year mark following surgery. Results show that
high-risk posteriors from the prognostic model are strongly
associated with the 5-year survival probabilities (Fig. 2B). Patients
with a high probability of tumor recurrence tend to be more likely
to have treatment failure after surgery. This indicates that the
high-risk posterior probability computed by the model is a good
prognostic factor of lung cancer survival. The wide 95%
confidence interval at posteriors ranging from 0.35 to 0.6
(Fig. 2B) might be due to the small sample size in this distribution
(Fig. 2A). Furthermore, a posterior of 0.5 means that the chance of
tumor recurrence is random, which also leads to a looser
confidence interval.
Using the prognostic categorization scheme described above,
the 12-gene signature separated patients into high- and low-risk
groups with significantly distinct (log-rank P=6.96e-7) post-
operative survival on the training cohort in Kaplan-Meier
analysis (Fig. 3A). This scheme generated significant patient
stratification on independent validation sets MSK (log-rank
P=9.88e-4; Fig. 3B) and DFCI (log-rank P=2.57e-4; Fig. 3C).
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94% in the studied cohorts, representing a significantly better
prognosis compared with the corresponding high-risk groups for
which the 3-year survival ranges from 48% to 63%. When 3-year
survival was used to define high- and low-risk groups (high-risk:
death within 3-y; low-risk: alive after 3-y), the 12-gene risk
algorithm achieved a sensitivity (correctly predicted high-risk
patients) of 73.65% in the training set, 86.96% in MSK, and
68.18% in DFCI, and a specificity (correctly predicted low-risk
patients) of 59.21% in the training set, 57.75% in MSK, and
76.36% in DFCI (Table S9). The sensitivity and specificity of the
12-gene signature in predicting 5-year survival is also provided in
Table S9.
In current practice, treatment for patients diagnosed with
NSCLC is based on AJCC tumor stage. Surgical resection is the
major treatment option for stage I NSCLC patients. However,
about 35–50% of stage I NSCLC patients will develop and die
from tumor recurrence within the five years following surgery
[2,3]. On the other hand, stage IB patients who received surgical
resection followed by adjuvant chemotherapy showed improved
survival rate [22]. Thus, we sought to explore whether the 12-gene
signature could identify specific high-risk patients with stage I
tumors. Results show that the 12-gene prognostic signature could
reliably identify high-risk patients with stage I tumors on both the
training cohort (results not shown) and two validation cohorts (log-
rank P=0.04; Fig. 3D and 3E). The prognostic model also
Figure 1. Overview of the study design for the identification of the 12-gene signature with combinatorial gene selection scheme
and the construction of the expression-defined prognostic model.
doi:10.1371/journal.pone.0012222.g001
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stage IB patients in the combined test sets (Fig. 3F). The 12-gene
signature did not generate significant prognostic stratification on
the stage IA patients (results not shown). These results demonstrate
that the identified 12-gene signature is independent of and
provides more refined prognosis than the current AJCC staging
system. Using this model, stage I NSCLC patients could be
advised to receive adjuvant chemotherapy according to the
expression profiles of the 12 gene markers.
Treatment selection for stage I and II NSCLC patients
based on the 12-gene signature
In order to assess whether the 12-gene signature could be used
for treatment selection for stage I and II non-small cell lung
cancers, patients who did not receive chemotherapy were selected
for further analysis. The prognostic model separated high- and
low-risk stage I patients without chemotherapy in the training
(UM & HLM; log-rank P=0.04; Fig. 4A) and test cohorts (MSK &
DFCI; log-rank P=0.02; Fig. 4B). Similarly, the model differen-
tiated high- and low-risk stage II patients without chemotherapy in
the training (log-rank P=0.06; Fig. 4C) and test cohorts (log-rank
P=0.03; Fig. 4D) in Kaplan-Meier analyses. The results indicate
that this gene expression-defined prognostic model could reliably
select patients with early stage NSCLC for adjuvant chemother-
apy. Meanwhile, it could also spare some stage I and II NSCLC
patients from chemotherapy based on the expression patterns of
the identified gene markers in the tumors.
Prognosis evaluation of the 12- gene signature with
clinical covariates
To confirm the prognostic power of the identified 12-gene
signature, the expression-defined prognostic model was evaluated
with commonly used prognostic factors of lung cancer, including
gender, age, and tumor stage on the combined testing cohorts
(DFCI and MSK). The posterior probability of high-risk, termed
as 12-gene risk score, was used as a covariate in the multivariate
Cox analysis (Table 3). Without the 12-gene risk score, tumor
stage was the only factor significantly (P,0.00006) associated with
elevated risk of lung cancer death. When the 12-gene risk score
was added to the multivariate Cox model, the 12-gene risk score
Table 1. The identified 12-gene lung cancer prognostic signature.
Gene Probe Set ID Protein Functions Classification
ATP6V0D1 212041_at ATPase Metabolism
PKLR 222078_at Pyruvate kinase Metabolism
SCLY 219808_at Catalyzes the decomposition of L-selenocysteine to L-alanine and
elemental selenium
Metabolism
SMPD1 209420_s_at Converts sphingomyelin to ceramide Metabolism
DLC1 210762_s_at A candidate tumor suppressor gene Oncogene
PDPK1 204524_at Cell signal protein Oncogene
ZAK 218833_at Cell signal protein Oncogene
STK24 208855_s_at Protein kinase Signaling Transduction
XPO1 208775_at Mediates nuclear export of cellular proteins Signaling Transduction
LMF1 46142_at Maturation of specific proteins in the endoplasmic reticulum Structure
FAM164A 205308_at Unknown N/A
CCDC99 221685_s_at Cell cycle Signaling Transduction
doi:10.1371/journal.pone.0012222.t001
Table 2. Parameters estimated in the 12-gene Naı ¨ve Bayes classifier.
Gene (attribute) Low-risk mean (mLi) Low-risk standard deviation (sLi) High-risk mean (mHi) High-risk standard deviation (sHi)
LMF1 101.6708 31.6461 88.6869 29.5986
DLC1 868.5886 578.3862 648.4284 530.6969
PKLR 14.3474 6.872 11.002 5.5501
ATP6V0D1 1388.054 398.6874 1209.6369 325.7233
CCDC99 277.1923 56.2284 300.0086 60.678
SCLY 58.3824 13.2988 63.6222 13.7703
PDPK1 297.6373 117.3514 253.7384 103.0455
FAM164A 264.8707 106.5128 223.8295 96.6066
SMPD1 278.5686 84.5316 239.3571 65.4393
XPO1 1674.3741 344.9824 1824.6274 400.4278
ZAK 132.694 67.7063 159.0546 79.1456
STK24 2248.6647 529.6098 2457.9982 576.496
doi:10.1371/journal.pone.0012222.t002
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(hazard ratio=3.94, 95% CI: [2.07, 7.52]), and tumor stage
remained significant (Table 3). Similarly, a comprehensive
evaluation was carried out with all available clinical covariates
and demographic data in the dataset, including smoking history,
race, and tumor differentiation (Table 4). In this comprehensive
evaluation, the 12-gene risk score remained a highly significant
prognostic factor with a hazard ratio of 4.19 (95% CI: [2.08,
8.46]). In both multivariate analyses, the hazard ratios of the 12-
gene risk score algorithm were higher than other clinical covariates
except tumor stage (III vs. I), while there is no significant difference
between the hazard ratio of the 12-gene signature and tumor
stage. These results demonstrate that the 12-gene signature is a
more accurate prognostic factor than some commonly used
clinical parameters.
Comparison with other lung cancer gene signatures
In the study by Shedden et al. [19], prognostic classifiers were
constructed with gene expression signatures alone or gene
expression signatures combined with clinical covariates. Among
twelve gene signatures identified in their study (Table S7), the best
signature was reported as ‘‘method A’’ (referred to as ‘‘Shedden A’’
in this study), which contains about 9,591 genes/probes. In order to
compare the predictive performance of our prognostic model with
their best model, the estimated hazard ratio and the concordance
probability estimate (CPE) of the models were evaluated. Hazard
ratios greater than 1 indicate that patients with high predicted risk
scores have poor clinical outcome. The model has strong predictive
power if the CPE value is close to 1; CPE value close to 0.5 indicates
that the model has poor predictive power (comparable to random
prediction). Results show that the proposed 12-gene signature has
the highest hazard ratio and CPE in both test sets when compared
to the gene signatures from Shedden et al. [19] (Fig. 5).
To evaluate the 12-gene signature with previously published 14
lung cancer signatures [12,13,16–19,22–25] (Table S6), Gene Set
Enrichment Analysis (GSEA) was used to assess the enrichment of
these signatures on 5-year survival. The normalized enrichment
score (NES) and its corresponding false discovery rate (FDR)
associated with each gene signature were evaluated on all 442
samples used in this study. In general, a gene set with high NES
and low FDR is desired, as it indicates that the gene set expresses
diversely with respect to the clinical outcome and the finding is
unlikely to be by chance. In comparison to 14 other published
gene signatures, the 12-gene signature exhibits high enrichment in
patient group whose survival is longer than 5-year with
significantly low FDR (absolute NES=1.5; FDR,0.10) (Fig. S1).
In this analysis, the most enriched signature with the lowest FDR
was SHEDDEN_MH of 244 genes (absolute NES=2.00;
FDR,0.002). Overall, among the 15 gene sets studied, the 12-
gene signature is one of the best lung cancer signatures evaluated
with GSEA.
RT-PCR Validation of gene expression patterns
In order to further confirm the expression patterns of the
identified 12 genes, RT-PCR microfluidic low density arrays
were used to analyze independent NSCLC tumor samples. First,
the 12-gene expression patterns obtained from both microarray
and RT-PCR were compared in terms of lymph node metastasis
(Fig. 6A). On the RT-PCR data normalized with POLR2A,g e n e
expression fold changes of the 12 genes in lymph node positive
(LN+) versus lymph node negative (LN2) samples were
compared with those in microarray data from Shedden et al
[19]. The results show that the mRNA expression patterns of the
12-gene signature measured in both platforms are concordant in
terms of lymph node metastasis. Then, to confirm the gene
expression patterns in terms of overall survival, fold changes
Figure 2. Association of the 12-gene risk score algorithm and lung cancer survival. (A). Histogram showing the distribution of the risk
scores (posterior probabilities of high-risk) in 442 lung adenocarcinoma patients. (B). Average rate of death at five years after surgery corresponding
to 12-gene risk score (posterior possibility). The dotted lines represent 95% confidence interval.
doi:10.1371/journal.pone.0012222.g002
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years) groups were also compared (Fig. 6C). Three-year survival
was used to keep the balance of the high-risk (n=11) and low-risk
(n=12) groups in the RT-PCR cohort. All gene markers
exhibited consistent expression patterns in over survival except
XPO1 in both platforms.
Prediction of chemoresponse in NCI-60 cell lines
After substantiating the clinical relevance of the 12-gene
signature in predicting lung adenocarcinoma overall survival, we
sought to explore whether the signature can predict chemor-
esponse to anti-lung cancer agents, including Cisplatin, Carbo-
platin, Paclitaxel, Etoposide, Erlotinib, and Gefitinib. Here, the
NCI-60 cell lines, regardless of tissue origin, were used in the
study. For each drug, cancer cell lines that are either sensitive or
resistant to the drug were included to build a chemoresponse
classifier based on the 12-gene expression profiles in the cell lines.
The performance of the classifiers was evaluated with leave-one-
out cross validation (Table 5). Statistical significance of the
classification was evaluated by comparing the overall accuracy of
the 12-gene signature with that of 1000 random signatures of the
same size using the same algorithm. The overall prediction
accuracy of chemoresponse was 81% (P,0.004) for Paclitaxel
(Taxol), 78% (P,0.001) for Carboplatin, 80% (P,0.005) for
Cisplatin, 73% (P,0.017) for Etoposide, 79% (P,0.001) for
Erlotinib, and 94% (P,0.001) for Gefitinib. These results
demonstrate that the 12-gene signature accurately predicted
sensitivity and resistance to common lung cancer chemotherapeu-
tic agents in cancer cell lines.
The differential expression in sensitive and resistant lung cancer
cell lines was analyzed for each signature gene. The drug responses
of the lung cancer cell lines in the NCI-60 panel were provided in
Table S8. Among the signature genes, the over-expression of
STK24 was linked to chemoresistance to all the studied drugs
except Gefitinib in the lung cancer cell lines; whereas the over-
expression of FAM14A was associated with chemosensitivity to all
the studied drugs except Gefitinib in lung cancer cell lines. The
under-expression of STK24 was associated with resistance to
Gefitinib (P,0.05). The under-expression of CCDC99 was
observed in resistance to Paclitaxel (P,0.05). The over-expression
of DLC1 was associated with chemoresistance to Erlotinib
(P,0.05), Paclitaxel, and Cisplatin; whereas its under-expression
Figure 3. Kaplan-Meier analyses of the 12-gene prognostic model in patients with resectable lung adenocarcinoma. The model
stratified patients into two significantly distinct (log-rank P,6.96e-7) prognostic groups in the training set (A) in 10-fold cross validation. The training
model was applied to two test sets (B and C) and generated significant patient stratification. This model separated (log-rank P,0.04) stage I patients
in both test sets (D and E) as well as stage IB patients (log-rank P,4.73e-3) from test sets (F).
doi:10.1371/journal.pone.0012222.g003
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(not statistically significant) (Fig. 7).
EGFR mutation is a well known factor in drug response to
Gefitinib and Erlotinib. In the NCI-60 cell lines, EGFR mutation
was detected only in the SK-MEL-28 melanoma and RPMI-8226
myeloma lines, but not in any lung cancer cell lines [26].
We analyzed the raw expression levels of EGFR probe sets.
Specifically, a fold change of 1.76 over-expression of EGFR
(210984_x_at) was observed in Erlotinib resistant vs. sensitive lung
cancer cell lines (P,0.05), whereas no significant differential
expression of EGFR was observed in other studies drugs (results not
shown). In the overall patient cohorts (n=442) from Shedden et al
[19], EGFR expression was not significantly associated with lung
cancer overall survival in univariate Cox modeling.
Figure 4. Evaluation of the 12-gene signature in treatment selection. The 12-gene signature separated high- and low-risk groups from
patients who did not receive chemotherapy (log-rank P,0.05) in the following cohorts: (A) stage I patients from the training cohort, (B) stage I
patients from two test cohorts, (C) stage II patients from the training cohort, (D) stage II patients from the two test cohorts.
doi:10.1371/journal.pone.0012222.g004
Refined Lung Cancer Prognosis
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Having established the clinical relevance of the 12-gene
prognostic signature, we sought to explore the functional
involvement of this gene set in lung tumorigenesis and tumor
progression. Two functional pathway analysis tools, Ingenuity
Pathway Analysis (IPA) and Pathway Studio 7.0, were used to
obtain curated molecular interactions related to the 12 genes.
Results from IPA show that the signature genes interact with
major cancer signaling pathways, such as TNF and AKT (Fig. 8A).
Pathway Studio 7.0 was used to find interactions among the 12
genes and 13 major lung cancer hallmarks (EGF, EGFR, KRAS,
MET, RB1, TP53, E2F1, E2F2, E2F3, E2F4, E2F5, AKT1, and
TNF) reported in the literature. Pathway Studio revealed various
types of interactions ranging from regulation to protein modifica-
tion among the 12 genes and eight out of 13 cancer hallmarks
(Fig. 8B). The functional pathway analysis suggests that the 12
signature genes are involved in lung cancer oncogenesis and tumor
progression.
Discussion
Lung cancer remains the leading cause of death worldwide. It is
important to identify clinically relevant prognostic biomarkers to
develop personalized treatment. More importantly, the discovered
biomarkers may reveal fundamental molecular mechanisms of this
deadly disease, and enhance our understanding of why patients
with certain tumor molecular characteristics have a poor clinical
outcome and how their outcome could be improved.
This study presents a hybrid model system for the identification
of a 12-gene signature for lung cancer prognosis and chemor-
esponse prediction. The 12-gene signature accurately quantifies
survival in patients with resectable lung adenocarcinoma, and
provides significant prognostic categorization within stage I and IB
patients, respectively. This signature reliably identified high-risk
patients within stage I and II who did not receive chemotherapy.
The gene expression-defined risk score is a more accurate
prognostic factor than commonly used clinical parameters. This
prognostic signature also predicts chemoresistance and chemosen-
sitivity to several major anti-lung cancer drugs in NCI-60 cancer
cell lines. Together, the results indicate that the 12-gene signature
could be used to select early stage lung adenocarcinoma patients at
high risk for tumor recurrence for adjuvant chemotherapy.
Meanwhile, it may spare stage I and II low-risk patients from
unnecessary chemotherapy. Furthermore, the 12-gene signature
has the potential to be used to inform physicians which anticancer
Table 3. Multivariate Cox proportional analysis of 12-gene
risk score and major clinical covariates including gender, age,
and tumor stage on testing cohorts (DFCI and MSK).
Variable* P-value Hazard Ratio (95% CI)
y
Analysis without 12-gene risk score
Gender (Male) 0.22 1.34 (0.84–2.16)
Age at diagnosis (.60) 0.08 1.61 (0.95–2.74)
Tumor Stage
Stage II 6.25E-05 2.91 (1.72–4.91)
Stage III 1.09E-05 4.16 (2.20–7.85)
Analysis with 12-gene risk score
Gender (Male) 0.17 1.40 (0.87–2.26)
Age at diagnosis (.60) 0.29 1.34 (0.78–2.31)
Tumor Stage
Stage II 3.47E-04 2.61 (1.54–4.43)
Stage III 7.40E-06 4.31 (2.28–8.16)
12-gene risk score 3.10E-05 3.94 (2.07–7.52)
*Gender was a binary variable (0 for female and 1 for male); age at diagnosis
was a binary variable (0 for ,60 years old and 1 otherwise); tumor stage was




Table 4. Multivariate Cox proportional analysis of all available
clinical covariates and 12-gene risk score on testing cohorts
(DFCI and MSK).
Variable* P-value Hazard Ratio (95% CI)
y
Analysis without 12-gene risk score
Gender (Male) 0.43 1.22 (0.74–1.99)
Age at diagnosis (.60) 0.05 1.70 (0.99–2.92)
Race
Others/Unknown 0.28 0.43 (0.09–1.97)
White 0.10 0.28 (0.06–1.28)
Tumor differentiation
Moderately differentiated 0.14 0.53 (0.23–1.24)
Poorly differentiated 0.70 1.17 (0.53–2.61)
Smoking history
Smokers 0.62 0.84 (0.43–1.66)
Unknown 0.91 0.89 (0.11–7.10)
Tumor Stage 3.31E-04 2.72 (1.57–4.69)
Stage II 2.38E-05 4.93 (2.35–10.33)
Stage III 0.43 1.22 (0.74–1.99)
Analysis with 12-gene risk score
Gender (Male) 0.38 1.25 (0.76–2.08)
Age at diagnosis (.60) 0.12 1.56 (0.89–2.72)
Race
Others/Unknown 0.52 0.60 (0.13–2.77)
White 0.11 0.29 (0.07–1.32)
Tumor differentiation
Moderately differentiated 0.17 0.56 (0.24–1.29)
Poorly differentiated 0.83 0.91 (0.41–2.06)
Smoking history
Smokers 0.61 0.84 (0.43–1.64)
Unknown 0.79 0.75 (0.09–5.98)
Tumor Stage
Stage II 1.37E-03 2.44 (1.41–4.22)
Stage III 5.12E-06 5.88 (2.75–12.58)
12-gene risk score 6.34E-05 4.19 (2.08–8.46)
*Gender was a binary variable (0 for female and 1 for male); age at diagnosis
was a binary variable (0 for ,60 years old and 1 otherwise); race was a
categorical variable of 3 categories (African American [as the reference group],
White, and Others [composed of Asian (5), Hawaiian or Pacific Islander (1), and
unknown]); tumor grade was categorical variable of 3 categories (Well [as the
reference group], Moderately, and Poorly differentiated); Smoking history was a
categorical variable of 3 categories (Non-smokers, Smokers, and Unknown);
tumor stage was categorical variable of 3 categories (Stage I [as the reference
group], Stage II, and Stage III).
ydenotes confidence interval.
doi:10.1371/journal.pone.0012222.t004
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expression patterns of the 12-gene signature were confirmed in
RT-PCR. Curated interactions between the signature genes and
major cancer signaling hallmarks revealed in the functional
pathway analysis provides further evidence that the 12-gene
signature might be involved in lung cancer oncogenesis and tumor
progression.
In the post-genomic era, innovative computational models are
needed to identify clinically important disease markers. Given the
current scale of high throughput data, a combinatorial gene
selection scheme is needed at different stages of gene filtering.
The choice to use a different feature selection technique depends
on an evaluation with an independent classifier. If the
classification performance cannot be further improved with the
current algorithm, a different algorithm will be used to reduce the
feature space. In this study, SAM and t-tests was used to identify
candidate genes showing differential expression between two
prognostic groups in the training set. SAM method is very similar
to t-test. We used t-tests (P,0.01) to select genes with certain level
of differential expression between two prognostic groups, and
used SAM to control for false discovery rate (FDR,25%). The
results from SAM and t-test are not exactly the same, because the
SAM method adds a constant (s) in the denominator to ensure
that genes with a very small variance in the samples and a small
differential expression are not selected as significant markers.
When s=0, SAM is exactly the same as t-test [21]. In our study,
genes that met both criteria (P,0.01 in t-tests and FDR,25% in
SAM) were included for further analysis. From this candidate
gene pool, Relief was then used to rank the importance of these
genes in terms of prognostic classification for the selection of the
final gene signature. This hybrid system was able to identify a
small set of genes that are more accurate than previously
published lung cancer gene signatures on the same datasets. We
have experimented to change the threshold in SAM statistics. As
a result, there were 87 genes with a FDR,10% and no genes
were selected with a FDR,1% from the training set. The 87
genes were not able to generate significant stratification in all
three patient cohorts. These results indicate that using SAM
method alone is not sufficient to identify the most accurate
prognostic gene signature. The hybrid models combining pooled
variance t-tests and Relief algorithm also identified a 15-gene
signature (Table S1). Among the two gene signatures, 16 genes
(Table S2) share common biological functions (Table S5). The
performance of these gene signatures (fitted as covariates in Cox
model) is comparable to that of the 12-gene signature (Tables S3,
S4 and S9; Fig. S2). The 15-gene signature was also validated
with RT-PCR analysis of independent NSCLC tumor samples
(Fig. S3). Overall, the hybrid models presented in this study are
Figure 5. Comparison of the 12-gene risk score algorithm and various models presented by Shedden et al. [19] in two test sets in
term of hazard ratios (A) and concordance probability estimate CPE (B).
doi:10.1371/journal.pone.0012222.g005
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PLoS ONE | www.plosone.org 9 August 2010 | Volume 5 | Issue 8 | e12222Figure 6. Comparison of expression patterns of 12 signature genes measured with DNA microarray and RT-PCR microfluidic low
density arrays (LDA). Gene expression fold change in lymph node positive (LN+) patients vs. lymph node negative (LN2) patients was compared
(A). Samples included in the fold change comparison were summarized in (B). Gene expression fold change in high-risk (death within 3-y) vs. low-risk
(alive after 3-y) groups was also compared on patients with follow-up information (C). The RT-PCR data was normalized with POLR2A in a sample-wise
manner. DNA microarray data were obtained from Shedden et al [19]. An asterisk (*) was put above a bar if that gene showed significant differential
expression in t-tests (P,0.05).
doi:10.1371/journal.pone.0012222.g006
Table 5. Prediction accuracy of chemoresponse in NCI-60 cell lines using the 12-gene signature.
Drug Sensitivity (chemoresistance) Specificity (chemosensitivity) Overall accuracy P-value*
Carboplatin 76% (19/25) 80% (16/20) 78% (35/45) ,0.001
Paclitaxel 72% (8/11) 87% (13/15) 81% (21/26) 0.004
Cisplatin 85% (22/26) 74% (14/19) 80% (36/45) 0.005
Etoposide 80% (16/20) 67% (14/21) 73% (30/41) 0.017
Erlotinib 79% (11/14) 80% (16/20) 79% (27/34) 0.001
Gefitinib 92% (11/12) 95% (20/21) 94% (31/33) ,0.001
*A P-value,0.05 represents that the overall accuracy of the 12-gene signature is significantly higher than that of random gene signatures with the same size usingt h e
same classifier in 1000 tests.
doi:10.1371/journal.pone.0012222.t005
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general.
Materials and Methods
Microarray profiles and patient samples
Gene expressions profiles analyzed in this study include 22,283
probes quantified with Affymetrix HG-U133A on 442 lung
adenocarcinoma samples from Shedden et al [19]. This study
cohort contains four data sets (University of Michigan, H. Lee
Moffitt Cancer Center, Memorial Sloan-Kettering Cancer Center,
and Dana-Farber Cancer Institute) contributed by six institutions.
Tumors were collected by surgical resection from patients who
have provided consent and protocols were approved by the
Institutional Review Boards (IRB-Med) of the respective institu-
tions. None of the patients received preoperative chemotherapy or
radiation and least two years of follow-up information was
available. Regions containing a minimum of 60% tumor cellularity
were required for macrodissection, and in most instances tumor
cellularity of at least 70–90% was identified for inclusion in the
sample for RNA isolation. The raw microarray data are available
from caArray website (https://array.nci.nih.gov/caarray/project/
details.action?project.id=182).
A total of 91 NSCLC specimens to be used in RT-PCR analysis
were obtained from West Virginia University Tissue Bank and the
Cooperative Human Tissue Network (CHTN) (Ohio State
University Tissue Bank, Columbus, OH). Tumor tissues were
collected in surgical resections and were snap-frozen and stored at
280uC until used for RNA extraction. This study was approved
with an IRB exemption from West Virginia University.
RNA extraction, and quality and concentration
assessments
Total RNA was extracted from snap-frozen tumor tissues using
a RNeasy Fibrous Tissue Mini Kit according the manufacturer’s
protocol (Qiagen, USA). Total RNA was eluted in 30 ml of RNase-
free water and stored at 280uC. The quality and integrity of the
RNA was evaluated by visualizing the gel image and electrophe-
rogram for each sample using the 2100 Bioanalyzer (Agilent
Technologies, CA). RNA assessed as having good quality from 74
tumor samples was included for further analysis. The RNA
concentration of each sample was determined using a Nanodrop-
1000 Spectrophotometer (NanoDrop Tech, Germany). Total
RNA samples were analyzed on an Agilent 2100 Bioanalyzer
RNA 6000 Nano LabChip.
Generation of complementary DNA (cDNA)
The reverse transcriptase polymerase chain reaction was used to
convert the high-quality single-stranded RNA samples to double-
stranded cDNA, using an Applied Biosystems GeneAmpH PCR
9600 machine (Foster City, CA). For standardization across all
samples, one microgram of RNA was used to generate cDNA.
Real-time RT-PCR low-density arrays
Real-time RT-PCR assays of an independent patient cohort of
NSCLC tumor samples were used to confirm the expression levels
of the identified signature genes in microarray platform. The
identified signature genes and three housekeeping genes were
included in the experiment. The three housekeeping genes, 18S,
UBC, and POLR2A, were selected due to their confirmed constant
mRNA expressions across samples [27].
We analyzed 74 tumor samples with high quality RNA using
TaqMan microfluidic low-density array (LDA) plates on an ABI
7900HT Fast RT-PCR instrument (Applied Biosystems). The
report was generated by the SDS2.3 software (Applied Biosys-
tems). In the report, the number of cycles required to reach
threshold fluorescence (Ct) and DCT for each sample relative to
the control gene defines the expression pattern for a gene. The
gene expression data were further analyzed using the 2{DDCT
method [28].
SAM statistics
Significance analysis of microarray (SAM) implemented in
MultiExperiment Viewer (MeV; downloaded from http://www.
tm4.org/mev.html) was used to identify statistically significant
genes. The relative difference of the expression levels of each gene
in two prognostic groups is computed and ranked (gene specific t-
tests). Null distribution of the relative difference of each gene is
generated by random permutations of patients’ prognostic group
labels. The expected relative difference of each gene is calculated
as the mean of the relative differences of this gene in the null
Figure 7. Genes with at least 1.5-fold expression fold change in resistant vs. sensitive lung cancer cell lines to four anticancer drugs.
In the graph, differential expression with statistical significance (P,0.05, t-tests) is marked by a red asterisk.
doi:10.1371/journal.pone.0012222.g007
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PLoS ONE | www.plosone.org 11 August 2010 | Volume 5 | Issue 8 | e12222Figure 8. Functional pathway analysis of the 12 signature genes. (A) Using core analysis from Ingenuity Pathway Analysis (IPA), curated
interactions were revealed among the identified signature genes and major lung cancer signaling pathways. (B) Six of the 12 signature genes also
exhibited various curated interactions with eight prominent lung cancer hallmarks with Pathway Studio 7.0.
doi:10.1371/journal.pone.0012222.g008
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from the expected relative difference by a certain threshold (delta)
were identified as significant genes. For a specific delta, SAM
provides a false discovery rate (FDR) based on the permutation
analysis of expression data [21].
Relief algorithm
Based on the genes selected with different variance t-tests and
SAM statistics, Relief was used to rank these genes with WEKA 3.4.
Relief evaluates the importance of a variable by repeatedly
sampling an instance and checking the value of the given variable
for the nearest instance from the same and different classes. The
values of the attributes of the nearest neighbors are compared to
the sampled instance and used to update the relevance scores for
each attribute. As approximated in following equation, Relief
computes the weight of attribute A as:
W½A ~P(different value of Ajnear miss){
P(different value of Ajnear hit)
Relief assigns more weight to those attributes that have the same
value for instances from the same class and differentiate between
instances from different classes [29,30].
Naı ¨ve Bayes classifier
Naı ¨ve Bayes algorithm is based on Bayes theorem with the
assumption that attributes are conditionally independent given the
target class. A new sample with attribute values ,a1, a2,…, ai.
would be classified into the most probable class based on posterior
probability and computed according to the Bayes theorem [31].
Specifically, the new sample would be classified into the class with
the highest posterior probability, based on the following equation:
Cpredicted~arg maxcj[C P(a1,a2,:::,aiDcj)P(cj)
where C is the set containing all the classes for the problem and cj is
a specific class.
Based on the conditional independence assumption, it holds
true for the situation that given a class of instances, the probability
of observing the conjunction of attributes a1, a2,…, ai would be
the product of the probability of the individual attributes:
P(a1,a2,:::,aiDcj)~P
i
P(aiDcj) [31]. Therefore, a simpler form of




In this study, the Naı ¨ve Bayes algorithm was used to classify 5-
year survival status in the training data with WEKA 3.4 [32].
Since gene expression is an attribute of continuous values, the
probability density function for normal distribution was estimated
to compute the probability of the gene in each class. Thus, the















where P(cj) is the prior for class j, mij and sij are estimated mean
and standard deviation for the i
th gene in class j.
Functional Pathway Analysis
Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City,
CA), and Pathway Studio 7.0 (Ariadne Genomics, Rockville, MD)
were used to derive curated molecular interactions, including both
physical and functional interactions, and pathway relevance. The
databases and software toolsets weigh and integrate information
from numerous sources, including experimental repositories and
text collections from published literature.
Gene Set Enrichment Analysis (GSEA.)
GSEA (http://broad.harvard.edu/gsea/) was used to evaluate
the enrichment of gene sets in prognostic groups defined by 5-year
survival. All measured genes are ranked according to the
differential expression between the two prognostic groups. An
Enrichment Score (ES) for each gene set is computed by going
through the ranked list from the top. ES is increased if the
encountered gene is a member of the gene set or decreased if
otherwise.
In this study, multiple gene sets were evaluated with the GSEA. In
Multiple Hypothesis Testing, prognostic group labels are randomly
permuted. A normalized enrichment score (NES) for each gene set is
generated by averaging enrichment scores from all permutations.
Statistical significance of the corresponding NES is indicated by false
discovery rate (FDR)i nt h ep e r m u t a t i o na n a l y s i s[ 3 3 ] .
Transcriptional Profiles in NCI-60 Cell Panel
Genome-wide mRNA expression profiles in NCI-60 cell lines
[34] were retrieved with CellMiner (http://discover.nci.nih.gov/
cellminer). The data were generated on Affymetrix U133A and
normalized using the GCRMA method [35]. The signature genes
were identified from the data file with gene symbols or UniGene
Cluster IDs (for unknown genes).
Drug activity profiles in NCI-60
The drug activity data in NCI-60 were retrieved from
Developmental Therapeutic Program at NCI/NIH through
DTP Data Search (http://dtp.nci.nih.gov/dtpstandard/dwindex/
index.jsp). The latest screening results for each studied drug were
used in the analysis. Growth inhibition was assessed from the
changes in total cellular protein after 48 hours of drug treatment
using a sulphorhodamine B assay. Drug activities (log10 GI50) were
recorded across the 60 human cancer cell lines. GI50 is the
concentration required to inhibit cell growth by 50% compared
with untreated controls. The activity profile of an agent consists of
60 such activity values, one for each cell line.
Defining Drug Sensitivity and Resistance
Drug activity data for Cisplatin, Carboplatin, Paclitaxel, and
Etoposide was processed to define drug resistance and sensitivity in
the NCI-60 lines as described before [36,37]. Specifically, for each
drug, log10 (GI50) values were normalized across the 60 cell lines.
Cell lines with log10 (GI50) at least 0.5 SDs above the mean were
defined as resistant to the drug. Those with log10 (GI50) at least 0.5
SDs below the mean were defined as sensitive to the drug. The
remaining cell lines with log10 (GI50) within 0.5 SDs were defined
as intermediate in the range of drug responses.
Classification of chemosensitivity/resistance
The mRNA expression profiles of the 12-gene lung cancer
signature were used to predict chemosensitivity/resistance in the
cancer cell lines. For each drug, only sensitive and resistant cell lines
were included in the analysis, while those with intermediate response
were excluded from classification. A k-nearest neighbor method
Refined Lung Cancer Prognosis
PLoS ONE | www.plosone.org 13 August 2010 | Volume 5 | Issue 8 | e12222was used to classify chemoresponse to Paclitaxel. Neural network
was used to classify drug response to Carboplatin, Gefitinib, and
Erlotinib. Boosting trees (AdaBoost) was used to classify response
to Etoposide. An ensemble learning method (Decorate) was used
in classifying chemoresponse to Cisplatin. The classification results
were evaluated with a leave-one-out cross validation. These
algorithms were implemented in WEKA 3.4 [32].
Differential expression analysis in resistant and sensitive
lung cancer cell lines
Using the average expression values of each gene in the lung
cancer cell lines in the NCI-60 panel, fold change of the gene
expression in resistant cell lines versus sensitive cell lines was
computed as follows:
Fold Change~2(Resistant Mean{Sensitive Mean)
Where Resistant_Mean is the mean expression of the group of resistant
cell lines and Sensitive_Mean is the mean expression of the group of
sensitive cell lines. In this study, a value of 1.5 (1.5 for over-expressed
and 0.67 for under-expressed) is the threshold used in deciding if a gene
is expressing differently. Statistical significance of the fold change is
computed using two-tail, unequal variance two-sample t-tests. It’s
considered statistically significant if a p-value is #0.05.
Statistical Analysis
In Kaplan-Meier analysis, log-rank tests were used to assess the
difference in probability of survival of different prognostic groups.
Hazard ratio and concordance probability estimate (CPE) were
used in the evaluation of different molecular prognostic signatures.
If the model gives hazard ratio greater than 1, it means that
patient samples predicted as high risk are more likely to have poor
outcome. CPE values close to 1 represents high concurrence and
good predictive power; CPE values close to 0.5 represents low
concurrence and poor predictive power. All the analyses were
performed with packages in R unless otherwise specified.
Supporting Information
Table S1 A 15-gene lung cancer prognostic signature. This gene
signature was identified using pooled-variance t-tests and RELIEF
algorithm. The expression of the 15 genes were used as covariates
in Cox model and median risk score from training set was used as
the cutoff point.
Found at: doi:10.1371/journal.pone.0012222.s001 (0.05 MB
DOC)
Table S2 A 16-gene signature sharing common biological
functions between 12- and 15-gene signatures (Table S5). Cox
model was fitted with these 16 gene expression levels and 75th
percentile of the risk scores from training set was used as the cutoff.
Found at: doi:10.1371/journal.pone.0012222.s002 (0.05 MB
DOC)
Table S3 Multivariate Cox proportional analysis of 15- and 16-
gene risk score with major clinical covariates in lung cancer
survival on testing cohorts (DFCI and MSK).
Found at: doi:10.1371/journal.pone.0012222.s003 (0.05 MB
DOC)
Table S4 Multivariate Cox proportional analysis of 15- and 16-
gene risk score with all clinical covariates in lung cancer survival
on testing cohorts (DFCI and MSK).
Found at: doi:10.1371/journal.pone.0012222.s004 (0.08 MB
DOC)
Table S5 Comparison of biological functions between 12-gene
signature and 15-gene signature with curated database. The
biological functions were obtained using Ingenuity Pathway
Analysis (IPA).
Found at: doi:10.1371/journal.pone.0012222.s005 (0.09 MB
DOC)
Table S6 14 published lung cancer gene signatures evaluated in
GSEA.
Found at: doi:10.1371/journal.pone.0012222.s006 (0.05 MB
DOC)
Table S7 Summary of gene selection and classification methods
of molecular classifiers compared in Fig. 5. Gene signatures A-N
were reported in (Shedden et al, 2008).
Found at: doi:10.1371/journal.pone.0012222.s007 (0.05 MB
DOC)
Table S8 Machine learning algorithm and genes used in
chemoresponse prediction using 12-gene signature.
Found at: doi:10.1371/journal.pone.0012222.s008 (0.05 MB
DOC)
Table S9 Sensitivity and specificity of the 12-, 15- and 16-gene
prognostic models.
Found at: doi:10.1371/journal.pone.0012222.s009 (0.05 MB
DOC)
Figure S1 Gene set enrichment analysis of the 12-gene signature
along with 14 published gene signatures for NSCLC. A summary
of the 14 gene signatures analyzed is listed in Table S6.
Found at: doi:10.1371/journal.pone.0012222.s010 (0.10 MB TIF)
Figure S2 Evaluation of the 15-gene, 12-gene, and 16-gene
prognostic models with molecular prognostic models presented by
Shedden et al (2008). Hazard ratio (A, C) and concordance
probability estimate (CPE) (B, D) were compared on patients in all
stages (A, B) and stage I (C, D) of lung cancer. Error bars in (A)
and (C) represent 95% confidence interval of hazard ratio.
Found at: doi:10.1371/journal.pone.0012222.s011 (0.15 MB TIF)
Figure S3 Comparison of gene expression patterns of the 15-
gene signature measured with DNA microarray and RT-PCR
microfluidic low density arrays (LDA). Gene expression fold
change in lymph node positive (LN+) patients vs. lymph node
negative (LN2) patients was compared (A). Samples included in
the fold change comparison are summarized in (B). On patient
with follow-up information, gene expression fold change in high-
risk patients vs. low-risk patients at 3-year period after surgery was
also compared (C). The RT-PCR data were normalized with
POLR2A in a sample-wise manner. DNA microarray data were
obtained from Shedden et al (2008). Red asterisk (*) above the bar
indicates the gene was differentially expressed t-test (P,0.05).
Found at: doi:10.1371/journal.pone.0012222.s012 (0.22 MB TIF)
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